Harvard Apparatus Regenerative Technology Reports Fourth Quarter and...
Harvard Apparatus Regenerative Technology, Inc. , a clinical stage biotechnology company developing regenerated organs for transplant, initially focused on the trachea, today reported unaudited financial results for the three months and year ended December 31, 2013.
Harvard Bioscience Management Discusses Q4 2013 Results - Earnings Call Transcript
Good day, ladies and gentlemen, and thank you for standing by. Welcome to the Fourth Quarter and Year-end 2013 Harvard BioScience's Earnings Conference Call.
Harvard Bioscience Reports Fourth Quarter and Year-End 2013 Results
Realigned the Company's global operations to increase efficiency and better position it for growth.
Harvard Bioscience reports Q4 continuing ops EPS 5c, one estimate
Harvard Bioscience sees FY14 EPS 26c, consensus 8c "The company said, "During the fourth quarter of 2013, we implemented several initiatives designed to improve our long-term business and financial results, and have already begun to benefit from those changes.
Harvard Apparatus Regenerative Technology Profiled by Xconomy.com
Harvard Apparatus Regenerative Technology, Inc. , a clinical stage biotechnology company developing regenerated organs for transplant, initially focused on the trachea, was featured in an article published by Xconomy.com on February 18. The article, "Ex-Harvard Bio Prez Leads Spin-Off's Plan to Make Engineered Organs," reviewed the rationale for ... (more)
Harvard Bioscience Inc. Schedules Fourth Quarter And Year-End 2013...
Harvard Bioscience, Inc. , a global developer, manufacturer, and marketer of a broad range of tools to advance life science research, will announce results for its fourth quarter and year ended December 31, 2013 before market trading hours on Thursday, February 27, 2014.